The effect of nicorandil on cardiac function and clinical outcomes in ST-segment elevation myocardial infarction patients undergoing primary percutaneous coronary intervention: a randomised trial.
Gitmez, Mesut ; Batman Eğitim ve Araştırma Hastanesi: Batman Egitim ve Arastirma Hastanesi, Batman Merkez/Batman, Turkey.
Lancellotti, Patrizio ; Centre Hospitalier Universitaire de Liège - CHU > > Service de cardiologie
Language :
English
Title :
The effect of nicorandil on cardiac function and clinical outcomes in ST-segment elevation myocardial infarction patients undergoing primary percutaneous coronary intervention: a randomised trial.
Choe JC, Oh J-H, Lee HC, et al. The effect of nicorandil on cardiac function and clinical outcomes in ST-segment elevation myocardial infarction patients undergoing primary percutaneous coronary intervention: a randomised trial. Acta Cardiol. 2023: 1–9.
Şaylık F, Akbulut T. The association of PRECISE-DAPT score with thrombus burden in patients with ST-segment elevation myocardial infarction. Acta Cardiol. 2022; 77 (5): 449–455.
Güler A, Gürbak İ, Panç C, et al. Frequency and predictors of no-reflow phenomenon in patients with COVID-19 presenting with ST-segment elevation myocardial infarction. Acta Cardiol. 2022; 77 (4): 313–321.
Hahn J-Y, Song YB, Oh J-H, SMART-DATE İnvestigators, et al. 6-month versus 12-month or longer dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome (SMART-DATE): a randomised, open-label, non-inferiority trial. Lancet. 2018; 391 (10127): 1274–1284.
Qian G, et al. Effects of nicorandil administration on ınfarct size in patients with ST-segment-elevation myocardial ınfarction undergoing primary percutaneous coronary ıntervention: the CHANGE trial. Circ Cardiovasc Interv. 2019; 12 (11): e008233.
